Hermetica Superfood Encyclopedia
The Short Answer
Galactan from Gracilaria changii contains bioactive compounds including hexadecanoic acid (palmitic acid), a phenolic hydroxypropanone derivative (compound 5), and hydroxylated fatty acids that collectively exert cytotoxic, antioxidant, acetylcholinesterase-inhibitory, and antibacterial effects through radical scavenging, enzyme inhibition, and membrane disruption. In preclinical in vitro assays, palmitic acid demonstrated cytotoxicity against HL-60 leukemia cells (IC50 0.50 ± 0.26 µg/mL) and MCF-7 breast cancer cells (IC50 1.50 ± 1.17 µg/mL), while compound 5 achieved 83.8 ± 2.6% DPPH radical scavenging and 64.7 ± 0.7% xanthine oxidase inhibition.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary KeywordGalactan Gracilaria changii benefits
Galactan — botanical close-up
Health Benefits
**Anticancer Cytotoxicity**
Hexadecanoic acid (palmitic acid) isolated from diethyl ether extracts inhibited proliferation of HL-60 leukemia cells (IC50 0.50 ± 0.26 µg/mL) and MCF-7 breast cancer cells (IC50 1.50 ± 1.17 µg/mL) in vitro, suggesting interference with mitochondrial function or induction of apoptotic pathways as assessed by MTT reduction assay.
**Antioxidant Activity**
The phenolic compound 1-(4'-methoxyphenyl)-3-(2",4",6"-trihydroxyphenyl)-3-hydroxypropanone (compound 5) demonstrated potent DPPH radical scavenging activity of 83.8 ± 2.6%, attributed to its trihydroxyphenyl moiety donating electrons to neutralize free radicals and reduce oxidative cellular damage.
**Xanthine Oxidase Inhibition**: Compound 5 inhibited xanthine oxidase by 64
7 ± 0.7%, an enzyme responsible for generating superoxide radicals and uric acid; this dual antioxidant-enzymatic action may confer potential benefit in managing oxidative stress-related conditions such as gout and hyperuricemia.
**Acetylcholinesterase Inhibition**
Palmitic acid exhibited acetylcholinesterase (AChE) inhibitory activity detectable at a minimum dose of 0.625 µg via TLC bioautography, suggesting potential relevance to cholinergic neurotransmission and preliminary interest in neurodegenerative disease research, though molecular docking data remain unavailable.
**Antibacterial Properties**
All five isolated compounds demonstrated antibacterial inhibition zones ranging from 8.4 to 14.0 mm against marine and pathogenic bacteria including Vibrio sp., with cholesterol (compound 2) achieving up to 12.6 ± 0.6 mm inhibition zones, likely through sterol-mediated disruption of bacterial membrane integrity.
**Hypolipidemic Effects**: Whole powdered G
changii fed to an animal model reduced plasma total cholesterol, LDL-C, triglycerides, and atherogenic index, consistent with the fiber (agar/galactan) and sterol content of the algae interfering with intestinal cholesterol absorption and lipoprotein metabolism.
**Anti-inflammatory Potential**
The polysaccharide galactan fraction and phenolic constituents of G. changii contribute to antioxidant and anti-inflammatory activity by reducing reactive oxygen species (ROS) and potentially modulating pro-inflammatory enzyme pathways, consistent with findings in related Gracilaria species showing DPPH IC50 approximately 27.3 GAE mg/100g.
Origin & History
Natural habitat
Gracilaria changii is a red marine macroalgae (Rhodophyta) native to the coastal waters of Southeast Asia, particularly Malaysia, where it grows in tropical and subtropical intertidal and subtidal zones on sandy or muddy substrates. It is cultivated commercially in Malaysian aquaculture systems, primarily as a source of agar for the food industry, and is harvested as an edible seaweed for local consumption. The species thrives in warm, nutrient-rich shallow marine environments and is among the most economically significant seaweed species in the Indo-Pacific region.
“Gracilaria changii has been consumed as an edible seaweed in Malaysian and broader Southeast Asian coastal communities for generations, valued primarily as a nutritious food source and as a raw material for agar extraction used in the food and biotechnology industries. In traditional Malaysian culinary practice, the fresh or dried thallus is incorporated into salads, dessert jellies (agar-agar), and cooked dishes, appreciated for its texture and mild flavor rather than for any formally codified medicinal role. Related Gracilaria species across the Indo-Pacific region have broader ethnobotanical records including use as emollient preparations, digestive aids, and hypolipidemic dietary supplements in traditional systems such as Chinese and Filipino folk medicine, practices that likely informed the scientific investigation of G. changii's bioactive properties. The modern scientific interest in G. changii emerged primarily from Malaysia's efforts to valorize its commercially cultivated seaweed biomass beyond agar production, leading to the phytochemical and bioactivity studies characterizing its cytotoxic and antioxidant compounds in the early 21st century.”Traditional Medicine
Scientific Research
The current evidence base for Galactan from Gracilaria changii is exclusively preclinical, comprising in vitro bioassays (n=3 replicates per compound) conducted on isolated diethyl ether extracts and one uncharacterized animal study examining whole powdered algae on lipid parameters; no peer-reviewed human clinical trials have been registered or published as of the available research record. Compound characterization was performed using rigorous analytical spectroscopy including IR, UV, GC-MS, and 2D NMR (HMQC, HMBC), supporting the structural identity of the five isolated bioactives, yet no pharmacokinetic, bioavailability, or in vivo dose-response data exist for the purified compounds. Cytotoxicity data against HL-60 and MCF-7 cell lines (IC50 values of 0.50–1.50 µg/mL for palmitic acid) and DPPH scavenging (83.8% for compound 5) are statistically reported but from small-replicate in vitro systems, limiting extrapolation to human clinical outcomes. The overall evidence is preliminary, characteristic of early-stage natural product discovery, and substantial translational research including mechanism elucidation, in vivo pharmacology, toxicology, and human trials is required before any clinical recommendations can be made.
Preparation & Dosage
Traditional preparation
**Whole Dried Seaweed (Traditional Food Form)**
Consumed as part of the diet in Malaysian coastal communities; no standardized therapeutic dose established; typical culinary use involves preparation as a salad, jelly, or cooked vegetable.
**Powdered Whole Algae (Animal Study Form)**
Used in preclinical hypolipidemic studies at an unspecified dose mixed into feed; no human-equivalent dose can be calculated from available data.
**Diethyl Ether Extract (Laboratory/Research Grade)**
Used exclusively in in vitro bioassays at concentrations of 0.625–50 µg/mL for cytotoxicity and AChE inhibition; not suitable or approved for human supplementation.
**Agar/Galactan Polysaccharide Fraction**
Commercially extracted from G. changii for food-grade agar production; consumed incidentally as a food additive/thickener with no established therapeutic dose.
**Standardization**
No standardized extracts with defined polyphenol, galactan, or palmitic acid content are commercially available for supplement use as of current evidence.
**Timing**
No clinical data to guide dosing timing; traditional food consumption is with meals.
Nutritional Profile
Gracilaria changii provides a nutritionally dense profile typical of red seaweeds, including moderate protein content (approximately 10–20% dry weight in related Gracilaria spp.), low fat (predominantly palmitic acid as the dominant fatty acid), and high dietary fiber in the form of galactan polysaccharides (agar; approximately 30–50% dry weight) that contribute to its hypolipidemic and prebiotic potential. The species is cited as a high vitamin C source, with ascorbic acid contributing to its antioxidant capacity alongside phenolic compounds; vitamin C concentrations in related Gracilaria species range from 50–200 mg/100g dry weight. Mineral content includes iodine, calcium, magnesium, and iron at concentrations typical of marine macroalgae, with bioavailability potentially limited by the presence of phytic acid analogs and algal cell wall polysaccharides. Phytochemicals include hexadecanoic acid, cholesterol, 2-hydroxymyristic acid, cholesteryl myristate, and the phenolic hydroxypropanone compound 5; the latter's bioavailability from whole seaweed matrix versus purified extract has not been formally characterized.
How It Works
Mechanism of Action
Palmitic acid (hexadecanoic acid) exerts cytotoxic effects against cancer cell lines by inhibiting mitochondrial dehydrogenase activity as assessed via MTT reduction, with evidence pointing to membrane lipid peroxidation and induction of intrinsic apoptosis pathways at sub-microgram concentrations; its AChE inhibitory activity at 0.625 µg likely involves competitive or non-competitive binding at the enzyme's active or peripheral anionic site, reducing acetylcholine hydrolysis. Compound 5, the trihydroxyphenyl hydroxypropanone, scavenges DPPH radicals through hydrogen atom transfer (HAT) or single electron transfer (SET) mechanisms mediated by its phloroglucinol-type ring system, and simultaneously inhibits xanthine oxidase (64.7 ± 0.7%) by competing with hypoxanthine or xanthine at the molybdopterin catalytic center, thereby reducing superoxide anion and uric acid generation. The antibacterial activity of sterols (cholesterol, cholesteryl myristate) and fatty acids is attributed to intercalation into bacterial phospholipid bilayers, increasing membrane permeability and disrupting the proton motive force, as evidenced by disk-diffusion inhibition zones of 8–14 mm. The hypolipidemic effect of whole G. changii in animal models is mechanistically consistent with soluble galactan polysaccharides forming viscous gels in the intestinal lumen that sequester bile acids, reducing enterohepatic cholesterol recycling and upregulating hepatic LDL receptor expression.
Clinical Evidence
No human clinical trials have been conducted on Galactan from Gracilaria changii or its isolated bioactive constituents, and the clinical evidence base is therefore absent at the human level. A single preclinical animal study reported reductions in plasma total cholesterol, LDL-C, triglycerides, and atherogenic index following dietary supplementation with powdered G. changii, but critical methodological details including species, sample size, dosage, duration, and statistical outputs were not reported in the available data, preventing assessment of effect size or confidence. In vitro cytotoxicity assays on HL-60 and MCF-7 cell lines provide proof-of-concept for anticancer activity but are insufficient to establish clinical efficacy or safety in humans. Clinicians and formulators should treat all reported benefits as hypothesis-generating findings pending adequately powered, peer-reviewed translational and human studies.
Safety & Interactions
No systematic human toxicology studies, formal adverse event reporting, or clinical drug interaction data exist for Galactan from Gracilaria changii or its isolated bioactive compounds, making a comprehensive safety assessment impossible at this time. Edible consumption as a whole food in Southeast Asian populations over many generations implies a general safety profile at culinary quantities, but the purified diethyl ether extract fractions demonstrating cytotoxicity (IC50 <2 µg/mL) at very low concentrations raise theoretical caution regarding concentrated supplemental doses outside a food matrix. Given the reported anticoagulant properties attributed to the galactan/sulfated polysaccharide fraction of related Gracilaria species, individuals taking anticoagulant or antiplatelet medications (e.g., warfarin, heparin, aspirin, clopidogrel) should exercise caution, as additive effects on coagulation pathways are biologically plausible but unconfirmed in G. changii specifically. Pregnancy, lactation, pediatric use, and renal or hepatic impairment populations have no documented safety data; use beyond normal dietary consumption is not recommended until adequate toxicological and clinical investigation is completed.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Gracilaria changiiGelang lautMalaysian red seaweedAgar seaweedRhodophyta galactan
Frequently Asked Questions
What are the main bioactive compounds in Gracilaria changii?
Five major compounds have been isolated from diethyl ether extracts of Gracilaria changii: hexadecanoic acid (palmitic acid), cholest-5-en-3-ol (cholesterol), 2-hydroxymyristic acid, cholesteryl myristate, and a phenolic hydroxypropanone designated compound 5. These were structurally confirmed by GC-MS and 2D NMR spectroscopy and collectively account for the species' cytotoxic, antioxidant, antibacterial, and acetylcholinesterase-inhibitory activities documented in preclinical assays.
Does Gracilaria changii have anticancer properties?
In vitro studies show that palmitic acid isolated from G. changii inhibits HL-60 leukemia cell proliferation with an IC50 of 0.50 ± 0.26 µg/mL and MCF-7 breast cancer cells with an IC50 of 1.50 ± 1.17 µg/mL, as assessed by MTT reduction assay. These results are promising at the cell-culture level but no animal tumor models or human clinical trials have been conducted, so anticancer claims in humans cannot be substantiated at this time.
Is Galactan from Gracilaria changii safe to consume?
Gracilaria changii has a long history of safe consumption as an edible seaweed in Malaysian and Southeast Asian diets, suggesting reasonable safety at culinary quantities. However, no formal toxicological studies, human safety trials, or established safe upper limits exist for concentrated extracts or isolated compounds, and individuals on anticoagulant medications should exercise caution due to the potential additive effects of the sulfated galactan polysaccharide fraction on blood coagulation.
What is the antioxidant activity of Gracilaria changii?
The phenolic compound 1-(4'-methoxyphenyl)-3-(2",4",6"-trihydroxyphenyl)-3-hydroxypropanone from G. changii achieved 83.8 ± 2.6% DPPH radical scavenging and 64.7 ± 0.7% xanthine oxidase inhibition in vitro, making it among the more potent antioxidant constituents described in this species. Additional antioxidant contribution comes from 2-hydroxymyristic acid (19.6 ± 0.5% DPPH scavenging) and the vitamin C content inherent in the whole seaweed matrix.
Can Gracilaria changii lower cholesterol?
One preclinical animal study reported that dietary supplementation with powdered G. changii reduced plasma total cholesterol, LDL-C, triglycerides, and atherogenic index, mechanistically consistent with the viscous galactan polysaccharide fiber sequestering bile acids in the gut. However, the study lacked reported sample sizes, dosages, species details, and statistical values, severely limiting the reliability of these findings, and no human clinical trials have confirmed a cholesterol-lowering effect.
How is Galactan extracted from Gracilaria changii, and does the extraction method affect its potency?
Galactan from Gracilaria changii is typically extracted using water-based or enzymatic methods that preserve the polysaccharide structure, with solvent selection (such as ethanol or aqueous extraction) influencing the final bioactive compound profile. Different extraction techniques can yield varying concentrations of galactan and associated compounds like hexadecanoic acid, potentially affecting the supplement's anticancer and antioxidant efficacy. Cold-water extraction methods tend to preserve heat-sensitive bioactives, while hot-water extraction may increase polysaccharide yield but reduce certain phenolic compounds.
Can Galactan from Gracilaria changii be taken with common medications, particularly chemotherapy or cholesterol-lowering drugs?
While Galactan from Gracilaria changii exhibits in vitro cytotoxic activity against cancer cells, concurrent use with chemotherapy drugs should be discussed with a healthcare provider, as polysaccharides may influence drug absorption or metabolism. If taking statins or other cholesterol medications, Galactan supplementation may potentiate effects due to its demonstrated cholesterol-lowering properties, potentially requiring dosage adjustments. No major direct drug interactions have been documented in clinical settings, but individual variation in response warrants medical supervision.
What is the typical recommended dosage of Galactan from Gracilaria changii, and how long does it take to see benefits?
There is no universally established clinical dosage for Galactan from Gracilaria changii, though traditional use and preliminary studies suggest ranges between 1–5 grams daily, depending on the extraction concentration and intended benefit. Most antioxidant and cholesterol effects observed in research occur within 4–8 weeks of consistent supplementation, though individual response varies based on diet, health status, and product quality. Standardized extracts with documented galactan content are preferable to ensure consistent dosing and efficacy.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w galactan-gracilaria-changii curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
